Patents Examined by Joseph Paul Miano
-
Patent number: 11976302Abstract: Provided herein are methods to increase the culture density and/or thickness of a cellular biomass in a cultivation infrastructure, to improve the culture of cells in the absence of serum in a cultivation infrastructure, and to promote anchorage-independent growth of a cellular biomass in a cultivation infrastructure. The methods comprise inhibiting the HIPPO signaling pathway, for example, by activating YAP1, activating TAZ, and/or inhibiting MOB1, LATS1 kinase, LATS2 kinase, WW45, MST1 kinase, and/or MST2 kinase in the cellular biomass. In some embodiments, the cellular biomass is harvested from the cultivation infrastructure for the formulation of cell-based food products or ingredients, such as animal meat manufactured from cells in an ex vivo process or for therapeutic applications such as organ or tissue transplantation or grafting.Type: GrantFiled: May 5, 2018Date of Patent: May 7, 2024Assignee: Upside Foods, Inc.Inventors: Nicholas J. Genovese, Meri Teresa Firpo, Daphné Dambournet
-
Patent number: 11965175Abstract: Embodiments are described that relate to methods and systems for growing cells in a hollow fiber bioreactor. In embodiments, the cells may be exposed to a number of growth factors including a combination of recombinant growth factors. In other embodiments, the cells may be grown in co-culture with other cells, e.g., hMSC's. In embodiments, the cells may include CD34+ cells.Type: GrantFiled: May 25, 2017Date of Patent: April 23, 2024Assignee: Terumo BCT, Inc.Inventor: Mark E. Jones
-
Patent number: 11944646Abstract: The present invention provides a composition comprising dendritic cells loaded with hHsp60sp, which dendritic cells are from a subject and have been fixed with paraformaldehyde (PFA). The subject may suffer from an autoimmune disease. Also provided are a method for preparing the composition; recombinant human cells comprising a heterologous gene encoding a fusion protein of HLA-E and hHsp60sp or B7sp, and expressing the fusion protein on the surface of the cells; a method for determining a percentage of maximum inhibition of testing the function of the HLA-E restricted CD8+ Treg cells from a subject, determining whether HLA-E restricted CD8+ Treg cells freshly isolated from a subject are defective, or determining whether defective HLA-E restricted CD8+ Treg cells from a subject are correctable; and a method for correcting defective HLA-E restricted CD8+ Treg cells, treating type 1 diabetes (T1D), or treating multiple sclerosis (MS).Type: GrantFiled: May 27, 2022Date of Patent: April 2, 2024Assignee: Avotres, Inc.Inventor: Hong Jiang
-
Patent number: 11930808Abstract: A method to obtain a composition comprising an enriched population of functional mesenchymal stem cells for hypothermic transport and local administration of said enriched population of functional mesenchymal stem cells in therapy. Finally also described is the use of said enriched population of functional mesenchymal stem cells, and compositions comprising them, obtained by the described method, in autologous or allogeneic treatment of diseases susceptible to mesenchymal stem cell therapy, either by local or systemic treatments, and more particularly in the treatment of osteoarticular diseases such as degenerative disc disease, osteoarthritis, and bone repair; in lupus erythematosus, graft-versus-host disease, and other autoimmune diseases; in peripheral vascular insufficiency and other cardiovascular diseases.Type: GrantFiled: September 18, 2019Date of Patent: March 19, 2024Assignees: UNIVERSIDAD DE VALLADOLID, CITOSPIN, S.L.Inventors: Ana Sánchez García, Francisco Javier García-Sancho Martín, Verónica García Díaz, Mercedes Alberca Zaballos, Sandra Güemes Gutiérrez
-
Patent number: 11898168Abstract: The current invention provides for methods of promoting differentiation of human pluripotent stem cells into esophageal progenitor cells as well as the cells obtained from the methods, solutions, compositions, and pharmaceutical compositions comprising such cells. The current invention also provides for methods of using the esophageal progenitor cells for treatment and prevention of disease, and kits.Type: GrantFiled: October 10, 2018Date of Patent: February 13, 2024Assignee: The Trustees of Columbia University in the City of New YorkInventors: Jianwen Que, Yongchun Zhang
-
Patent number: 11898166Abstract: Disclosed are methods of preparing thymic organoids according to embodiments of the invention. Also disclosed are methods of preparing thymic emigrant cells in vitro, according to embodiments of the invention. Also disclosed are methods of treating or preventing a condition in a mammal, e g., cancer.Type: GrantFiled: September 19, 2018Date of Patent: February 13, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Raul E. Vizcardo, Nicholas P. Restifo
-
Patent number: 11873509Abstract: By establishing effective methods for shrimp 3D cell culture and passage, the present invention provides a technology of continuous shrimp cell culture intended for the establishment of immortalized shrimp cell lines. The present invention provides a preparation method of matrigel for 3D cell culture of shrimp by optimizing an additive proportion of matrigel. The present invention further provides a technology of separation and 3D cell culture of shrimp haemolymph cells, where shrimp haemolymph cells adhere to and grow on the surface of the matrigel in the form of a single round cell and a cell pellet/cellular spheroid, with survival and growth abilities being superior to 2D culture effects. The above technology is achieved by optimizing a formula of complete medium for shrimp cells, selecting the medium as an anticoagulant and a diluent for shrimp haemolymph cells, selecting a 3D culture method for surface-adhered growth in the matrigel.Type: GrantFiled: April 28, 2020Date of Patent: January 16, 2024Assignee: Ocean University of ChinaInventors: Huarong Guo, Xin Song, Yang Zhou
-
Patent number: 11672832Abstract: The present disclosure provides compositions and methods employing stem cell-derived amnion tissue. In some embodiments, compositions (e.g., scaffolds and devices) and methods of generating amnion-like tissues from hPSCs are provided. In some embodiments, uses of such cells for research, compound screening and analysis, and therapeutics are provided.Type: GrantFiled: December 8, 2017Date of Patent: June 13, 2023Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Jianping Fu, Deborah Gumucio, Yue Shao, Kenichiro Taniguchi, Yi Zheng, Sajedeh Nasr Esfahani
-
Patent number: 11634686Abstract: Provided herein are compositions and methods for generation of naive human pluripotent stem cells. The method comprises incubation of iPSCs under 5% O2 in a medium comprising 5% glucose, an MEK inhibitor, a GSK3? inhibitor, human leukemia inhibitory factor (LIF), human insulin and Torin 1. The method does not need any other inhibitors or transgene expression. The naive human pluripotent cells can be used to generate a large amount of mature human cells from all three germ layers in host non-human animals.Type: GrantFiled: November 1, 2017Date of Patent: April 25, 2023Inventor: Jian Feng